Delfina Popiel

Dr. Delfina Popiel


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AMAgata Mikołajczyk
Agata Mikołajczyk
FMFilip Mitula
Filip Mitula
DPDelfina Popiel
Delfina Popiel
BBozena Kaminska
Bozena Kaminska
MWMaciej Wieczorek
Maciej Wieczorek
JPJerzy Pieczykolan
Jerzy Pieczykolan
Receptor tyrosine kinases (RTKs) are transmembrane receptors that bind growth factors and cytokines and contain a regulated kinase activity within their cytoplasmic domain. RTKs play an important role in signal transduction in both normal and malignant cells, and their encoding genes belong to the most frequently affected genes in cancer cells. The TAM family proteins (TYRO3, AXL, and MERTK) are involved in diverse biological processes: immune regulation, clearance of apoptotic cells, platelet aggregation, cell proliferation, survival, and migration. Recent studies show that TAMs share overlapping functions in tumorigenesis and suppression of antitumour immunity. MERTK and AXL operate in innate immune cells to suppress inflammatory responses and promote an immunosuppressive tumour microenvironment, while AXL expression correlates with epithelial-to-mesenchymal transition, metastasis, and motility in tumours. Therefore, TAM RTKs represent a dual target in cancer due to their intrinsic roles in tumour cell survival, migration, chemoresistance, and their immunosuppressive roles in the tumour microenvironment (TME). In this review, we discuss the potential of TAMs as emerging therapeutic targets in cancer treatment. We critically assess and compare current approaches to target TAM RTKs in solid tumours and the development of new inhibitors for both extra- and intracellular domains of TAM receptor kinases.

Verified
Journal Article
Open access
PDF file
JMJoanna Moes-Sosnowska
Joanna Moes-Sosnowska
MSMonika Skupińska
Monika Skupińska
ULUrszula Lechowicz
Urszula Lechowicz
ESEwa Szczepulska-Wojcik
Ewa Szczepulska-Wojcik
PSPaulina Skronska
Paulina Skronska
Joanna Chorostowska-WynimkoJoanna Chorostowska-Wynimko
Joanna Chorostowska-Wynimko
While fibroblast growth factor receptors (FGFRs) are involved in several biological pathways and FGFR inhibitors may be useful in the treatment of squamous non-small cell lung cancer (Sq-NSCLC), FGFR aberrations are not well characterized in Sq-NSCLC. We comprehensively evaluated FGFR expression, fusions, and variants in 40 fresh-frozen primary Sq-NSCLC (stage IA3–IV) samples and tumor-adjacent normal tissues using real-time PCR and next-generation sequencing (NGS). Protein expression of FGFR1–3 and amplification of FGFR1 were also analyzed. FGFR1 and FGFR4 median gene expression was significantly (p < 0.001) decreased in tumors compared with normal tissue. Increased FGFR3 expression enhanced the recurrence risk (hazard ratio 4.72, p = 0.029), while high FGFR4 expression was associated with lymph node metastasis (p = 0.036). Enhanced FGFR1 gene expression was correlated with FGFR1 protein overexpression (r = 0.75, p = 0.0003), but not with FGFR1 amplification. NGS revealed known pathogenic FGFR2,3 variants, an FGFR3::TACC3 fusion, and a novel TACC1::FGFR1 fusion together with FGFR1,2 variants of uncertain significance not previously reported in Sq-NSCLC. These findings expand our knowledge of the Sq-NSCLC molecular background and show that combining different methods increases the rate of FGFR aberrations detection, which may improve patient selection for FGFRi treatment.

12 January 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
DPDelfina Popiel
Delfina Popiel
ASAleksandra Stańczak
Aleksandra Stańczak
MSMonika Skupińska
Monika Skupińska
AMAgata Mikołajczyk
Agata Mikołajczyk
PSPaulina Stańczak
Paulina Stańczak
JPJerzy Pieczykolan
Jerzy Pieczykolan
Fibroblast Growth Factor Receptors (FGFRs) are a family of receptor tyrosine kinases expressed on a plethora of cell membranes. They play crucial roles in both embryonic development and adult tissue functions. There is an increasing amount of evidence that FGFR-mediated oncogenesis is mainly related to gene amplification, activating mutations, or translocation in tumors of various histological types. Dysregulation of FGFRs has been implicated in a wide variety of neoplasms, such as bladder, gastric, and lung cancers. Given their functional significance, FGFRs emerge as promising targets for cancer therapy. Here, we introduce CPL304100, an innovative and highly potent FGFR1–3 kinase inhibitor demonstrating excellent in vitro biological activity. Comprehensive analyses encompassed kinase assays, cell line evaluations, PK/PD studies surface plasmon resonance studies, molecular docking, and in vivo testing in mouse xenografts. CPL304110 exhibited a distinctive binding profile to FGFR1/2/3 kinase domains, accompanied by a good safety profile and favorable ADMET parameters. Selective inhibition of tumor cell lines featuring active FGFR signaling was observed, distinguishing it from cell lines lacking FGFR aberrations (FGFR1, 2, and 3). CPL304110 demonstrated efficacy in both FGFR-dependent cell lines and patient-derived tumor xenograft (PDTX) in vivo models. Comparative analyses with FDA-approved FGFR inhibitors, erdafitinib and pemigatinib, revealed certain advantages of CPL304110 in both in vitro and in vivo assessments. Encouraging preclinical results led the way for the initiation of a Phase I clinical trial (01FGFR2018; NCT04149691) to further evaluate CPL304110 as a novel anticancer therapy.

Verified
Journal Article
Open access
PDF file
APAnna Piotrowska
Anna Piotrowska
JNJoanna I. Nowak
Joanna I. Nowak
JWJustyna Wierzbicka
Justyna Wierzbicka
PDPaweł Domżalski
Paweł Domżalski
MGMonika Górska-Arcisz
Monika Górska-Arcisz
MZMichal Zmijewski
Michal Zmijewski
Regardless of the unprecedented progress in malignant melanoma treatment strategies and clinical outcomes of patients during the last twelve years, this skin cancer remains the most lethal one. We have previously documented that vitamin D and its low-calcaemic analogues enhance the anticancer activity of drugs including a classic chemotherapeutic—dacarbazine—and an antiangiogenic VEGFRs inhibitor—cediranib. In this study, we explored the response of A375 and RPMI7951 melanoma lines to CPL304110 (CPL110), a novel selective inhibitor of fibroblast growth factor receptors (FGFRs), and compared its efficacy with that of AZD4547, the first-generation FGFRs selective inhibitor. We also tested whether 1,25(OH)2D3, the active form of vitamin D, modulates the response of the cells to these drugs. CPL304110 efficiently decreased the viability of melanoma cells in both A375 and RPMI7951 cell lines, with the IC50 value below 1 µM. However, the metastatic RPMI7951 melanoma cells were less sensitive to the tested drug than A375 cells, isolated from primary tumour site. Both tested FGFR inhibitors triggered G0/G1 cell cycle arrest in A375 melanoma cells and increased apoptotic/necrotic SubG1 fraction in RPMI7951 melanoma cells. 1,25(OH)2D3 modulated the efficacy of CPL304110, by decreasing the IC50 value by more than 4-fold in A375 cell line, but not in RPMI7951 cells. Further analysis revealed that both inhibitors impact vitamin D signalling to some extent, and this effect is cell line-specific. On the other hand, 1,25(OH)2D3, have an impact on the expression of FGFR receptors and phosphorylation (FGFR-Tyr653/654). Interestingly, 1,25(OH)2D3 and CPL304110 co-treatment resulted in activation of the ERK1/2 pathway in A375 cells. Our results strongly suggested possible crosstalk between vitamin D-activated pathways and activity of FGFR inhibitors, which should be considered in further clinical studies.

25 March 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
AMAgata Mikołajczyk
Agata Mikołajczyk
DPDelfina Popiel
Delfina Popiel
KJKinga JastrzęBska
Kinga JastrzęBska
BWBartosz Wiernicki
Bartosz Wiernicki
FMFilip Mituła
Filip Mituła
MWMaciej Wieczorek
Maciej Wieczorek
Introduction: The TAM family of receptor tyrosine kinases (TYRO3, AXL, MERTK) promotes tumor survival, metastasis, and immune evasion. Its dysregulation across solid and hematologic cancers is associated with therapy resistance and poor outcomes. FLT3 is a key oncogenic driver in acute myeloid leukemia (AML). We report the preclinical characterization of CPL423, a low-molecular-weight inhibitor of all TAMs and FLT3. Method: In vitro kinase assays quantified potency and kinome selectivity. Antiproliferative effects were measured in FLT3-ITD-driven AML cell lines (MOLM-13, MV4-11). Antitumor efficacy was evaluated in AML xenografts and A375 melanoma (AXL overexpression, BRAF V600E mutation). Phagocytic capacity of antigen presenting cells was addressed using bone marrow derived dendritic cells (BMDC). Physicochemical, ADME/PK, and cardiovascular safety liabilities were profiled. Result: CPL423 inhibited TAMs and FLT3 with sub-nanomolar IC50s (MERTK 0.47 nM; FLT3 0.94 nM) and high selectivity. It suppressed proliferation in MOLM-13 and MV4-11 (IC50 5.7 and 7.92 nM). In AML xenografts, it achieved up to 98% tumor growth inhibition without observable toxicity; in A375, TGI was 39.4% at 50 mg/kg on day 14 Ex vivo experiments showed that the compound altered the clearance of dying cells by dendritic cells (BMDCs), consistent with TAM-pathway modulation. CPL423 showed high permeability, metabolic stability, and low cardiovascular liability. Discussion: CPL423 provides direct antitumor activity via dual TAM/FLT3 inhibition and immune-mediated effects on antigen-presenting cells, addressing resistance mechanisms in AML and TAM/AXL-driven solid tumors and supporting further development, including combination regimens.